Content about Specialty Pharmacy

November 2, 2010

The value of the market for specialty injectable drugs will top $90 billion by 2014,...

November 2, 2010

A company that develops drugs for treating autoimmune diseases and cancer has created a scientific...

CAMBRIDGE, Mass. A company that develops drugs for treating autoimmune diseases and cancer has created a scientific advisory board as part of its efforts to create treatments for Type 1 diabetes.

 

Tolerx said the four-member board would support the development of its lead drug candidate, otelixizumab, and guide future research and development in the Type 1 diabetes area.

 

 

November 1, 2010

Amgen's SVP research and development, Joe Miletich, urged members of a Food and Drug Administration...

THOUSAND OAKS, Calif. Amgen's SVP research and development, Joe Miletich, urged members of a Food and Drug Administration panel to establish approval standards for biosimilars that ensure patient safety and follow a science-based approach.

“Put patients first and sound policy will follow,” Miletich said. “Amgen believes biosimilars have a meaningful role to play in the healthcare system. However, dissimilar — unlike generic drugs — are not identical to the innovative biological products.” 

November 1, 2010

Specialty pharmacy provider BioScrip has promoted its COO, the company said Tuesday....

ELMSFORD, N.Y. Specialty pharmacy provider BioScrip has promoted its COO, the company said Tuesday.

 

BioScrip announced that COO Rick Smith was named CEO of the company, effective Jan. 1, replacing current CEO Richard Friedman. After stepping down, Friedman will serve as non-executive chairman of BioScrip’s board.

 

 

November 1, 2010

In testimony before the Food and Drug Administration on Tuesday, CVS Caremark’s SVP specialty pharmacy...

WOONSOCKET, R.I. In testimony before the Food and Drug Administration on Tuesday, CVS Caremark’s SVP specialty pharmacy operations, Scott Reid, reiterated the company’s support that the FDA implement regulations necessary to approve biogeneric drugs under the Affordable Care Act.

November 1, 2010

The Food and Drug Administration should ensure patient access, safety and efficacy; create a transparent...

WASHINGTON The Food and Drug Administration should ensure patient access, safety and efficacy; create a transparent and scientific regulatory structure; and enable innovation and competition when creating regulations governing follow-on biologics, according to testimony released in advance of an FDA hearing by a drug lobbying group.

October 31, 2010

In a big boost to its growing specialty pharmacy operation, drug-distribution and health services giant...

October 31, 2010

The U.S. subsidiary of a Swiss biotech company has started a late-stage trial of a...

October 28, 2010

British drug maker GlaxoSmithKline will work with U.S.-based Amicus Therapeutics to develop a drug for...

CRANBURY, N.J. British drug maker GlaxoSmithKline will work with U.S.-based Amicus Therapeutics to develop a drug for a rare genetic disease.

 

The two companies announced a deal to develop and commercialize Amigal (migalastat hydrochloride), a treatment for Fabry disease. Under the deal, GSK will pay Amicus $30 million upfront, as well as milestone payments of up to $170 million and royalties on future sales.

 

 

October 27, 2010

The Food and Drug Administration has approved a new usage for a blood cancer drug,...

October 25, 2010

An investigative vaccine made by Novartis appears to offer good protection against meningococcal disease in...

BASEL, Switzerland An investigative vaccine made by Novartis appears to offer good protection against meningococcal disease in infants, according to results of a late-stage clinical trial released Monday.

 

The Swiss drug maker said results of a phase-3 trial showed that Menveo (meningococcal group A, C, W135 and Y) induced immune responses in a high percentage of babies against four strains of the bacteria. Meningococcal disease occurs suddenly and can cause serious illness and often death during the first year of life.

 

 

October 25, 2010

Strativa Pharmaceuticals is working with a Swedish drug maker to develop and commercialize a prescription...

WOODCLIFF LAKE, N.J. Strativa Pharmaceuticals is working with a Swedish drug maker to develop and commercialize a prescription vitamin supplement, Strativa said Tuesday.

 

The company said it had signed a license and supply agreement with Swedish Orphan Biovitrum, also known as Sobi, concerning European rights to Strativa’s Nascobal (cyanocobalamin), a vitamin B12 nasal spray.

 

 

October 25, 2010

The temporary discontinuation of sales of a drug used by cancer patients led to a...

LAKE FOREST, Ill. The temporary discontinuation of sales of a drug used by cancer patients led to a slight dip in sales for Hospira during third quarter 2010, but the company nonetheless had strong sales overall, according to an earnings report released Tuesday.

 

October 24, 2010

In a highly anticipated move to new leadership, the National Community Pharmacists Association has named...

October 21, 2010

September same-store sales at Assured Pharmacy increased by 13.5% compared with last year, the specialty...

October 20, 2010

Combining two antiviral drugs for HIV may raise the risks of life-threatening heart problems, the...

October 20, 2010

The Food and Drug Administration has approved a biotech drug for treating cancer of the...

SOUTH SAN FRANCISCO, Calif. The Food and Drug Administration has approved a biotech drug for treating cancer of the stomach and esophageal junction.

 

Genentech, a subsidiary of Swiss drug maker Roche, announced Wednesday the approval of Herceptin (trastuzumab) as a treatment for cancer of the stomach that includes the HER2 gene and has spread to other parts of the body, when combined with chemotherapy. The drug has long since had approval as a treatment for HER2-positive breast cancer.

 

 

October 20, 2010

A pharmacy that specializes in serving patients with chronic medical conditions has received accreditation status...

October 19, 2010

Patients taking a certain class of drugs mostly used for prostate cancer may be at...

SILVER SPRING, Md. Patients taking a certain class of drugs mostly used for prostate cancer may be at higher risk of heart disease and diabetes, the Food and Drug Administration warned on Wednesday.

 

October 19, 2010

A specialty pharmacy provider is creating an online tool to train and educate new and...

October 17, 2010

A company that develops drugs for pain is hoping to get approval of one of...

SAN MATEO, Calif. A company that develops drugs for pain is hoping to get approval of one of its drugs for a pain condition associated with HIV.

October 14, 2010

Specialty pharmacy provider Amber Pharmacy has joined retailing cooperative Topco Associates, Amber said Friday....

October 14, 2010

The Food and Drug Administration has given orphan drug designation to a treatment for a...

STOCKHOLM The Food and Drug Administration has given orphan drug designation to a treatment for a rare kidney disease under mid-stage clinical development by privately owned Swedish drug maker PharmaLink, the company said.

 

The FDA granted the designation to Nefecon (PL-56), a treatment for IgA nephropathy, also known as Berger’s disease, a disorder that leads to end-stage kidney disease. The FDA gives orphan drug designation to incentivize development of treatments for rare and serious disorders.

 

 

October 13, 2010

Independent specialty pharmacy provider Axium Healthcare Pharmacy is celebrating 10 years in business, Axium said Wednesday....

October 12, 2010

The Food and Drug Administration approved a drug to treat and prevent relapse after patients...

SILVER SPRING, Md. The Food and Drug Administration approved a drug to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment.

Vivitrol is an extended-release formulation of naltrexone -- which works to block opioid receptors in the brain -- administered by intramuscular injection once a month. It only is administered by a physician.